New mapping tech aims to improve heart ablation for AFib patients
NCT ID NCT06808217
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This registry tracks 550 people with atrial fibrillation who are treated with the FARAPULSE pulsed field ablation system, using a special catheter and mapping technology. The goal is to see how safe and effective the procedure is in real-world settings over one year. Researchers will look at complications and how well the treatment controls the heart rhythm.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FARAPULSE Pulsed Field Ablation System (device)
What this could lead to
If successful, this could confirm that using the FARAPULSE system with advanced mapping improves safety and success rates for treating atrial fibrillation.
What could go wrong
This is an observational registry, not a randomized trial, so results may not prove cause and effect. Risks include procedure-related complications like bleeding or heart rhythm issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allgemeines Krankenhaus AKH
Vienna, Austria
-
Asklepios Klinik Saint Georg
Hamburg, Germany
-
CHRU de Clermont-Ferrand
Clermont-Ferrand, France
-
CHU Grenoble
Grenoble, France
-
CHU de Saint-Etienne
Saint-Priest-en-Jarez, France
-
Cardiocentro Ticino
Lugano, Switzerland
-
Centre Cardiologique du Nord
Saint-Denis, France
-
Centre Hospitalier Princesse Grace
Monaco, Monaco
-
Clinica Montevergine
Mercogliano, Italy
-
Clinique Pasteur
Toulouse, France
-
Eramus MC- University Medical Center
Rotterdam, Netherlands
-
Henry Dunant Hospital Center
Athens, Greece
-
Hospital Clinico San Carlos
Madrid, Spain
-
Hospital Europeen Georges-Pompidou (HEGP)
Paris, France
-
Hospital de Basurto
Bilbao, Spain
-
Hospital de la Pitie-Salpetriere
Paris, France
-
Ippokrateio General Hospital
Thessaloniki, Greece
-
Isala Klinieken
Zwolle, Netherlands
-
MVZ CCB Frankfurt und Main-Taunus GbR
Frankfurt, Germany
-
Mater Private Hospital
Dublin, Ireland
-
University Hospital Zurich
Zurich, Switzerland
-
Vivantes Klinikum Am Urban
Berlin, Germany